Cervical Disc Arthroplasty: Evolution, Evidence, and Future Directions in Motion-Preservation Surgery

➢ Cervical disc arthroplasty (CDA) provides clinical outcomes comparable with those of anterior cervical discectomy and fusion (ACDF) for 1-level and 2-level cervical degenerative disc disease (DDD), with durable long-term motion preservation. ➢ Although CDA is associated with lower rates of adjacent-segment pathology compared with ACDF, the absolute risk reduction at longer follow-up is modest and methodological heterogeneity across trials limits definitive conclusions. ➢ Expanded indications including multilevel (≥3-level) CDA, hybrid constructs, and other situations that were previously considered contraindicated during U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trials have shown promising short-term to intermediate-term results in more recent studies. ➢ As CDA utilization increases, standardized failure reporting and the development of evidence-based revision algorithms are critical to optimize long-term outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Bone and Joint Surgery
Published
2026-10-09
DOI
https://doi.org/10.2106/jbjs.26.00323
Primary Topic
Cervical and Thoracic Myelopathy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cervical Disc Arthroplasty: Evolution, Evidence, and Future Directions in Motion-Preservation Surgery

Graham Seow-Hng Goh, 이승준, Matthew T. Kim, K. Daniel Riew
Journal of Bone and Joint Surgery
Cervical and Thoracic Myelopathy
article

Cervical Disc Arthroplasty: Evolution, Evidence, and Future Directions in Motion-Preservation Surgery

Graham Seow-Hng Goh, 이승준, Matthew T. Kim, K. Daniel Riew
article en

Abstract

➢ Cervical disc arthroplasty (CDA) provides clinical outcomes comparable with those of anterior cervical discectomy and fusion (ACDF) for 1-level and 2-level cervical degenerative disc disease (DDD), with durable long-term motion preservation. ➢ Although CDA is associated with lower rates of adjacent-segment pathology compared with ACDF, the absolute risk reduction at longer follow-up is modest and methodological heterogeneity across trials limits definitive conclusions. ➢ Expanded indications including multilevel (≥3-level) CDA, hybrid constructs, and other situations that were previously considered contraindicated during U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trials have shown promising short-term to intermediate-term results in more recent studies. ➢ As CDA utilization increases, standardized failure reporting and the development of evidence-based revision algorithms are critical to optimize long-term outcomes.

Journal of Bone and Joint Surgery
Boston University (US), Boston Medical Center (US), Cornell University (US), Columbia University Irving Medical Center (US)
Openalex Percentile: Top 10%
Cervical and Thoracic Myelopathy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.